Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Iovance Biotherapeutics (IOVA) Return on Sales (2023 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Return on Sales for 5 consecutive years, with 0.83% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Sales rose 24.0% to 0.83% in Q4 2025 year-over-year; TTM through Dec 2025 was 1.48%, a 78.0% increase, with the full-year FY2025 number at 1.48%, up 78.0% from a year prior.
  • Return on Sales was 0.83% for Q4 2025 at Iovance Biotherapeutics, up from 1.35% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.83% in Q4 2025 to a low of 447.6% in Q2 2023.
  • A 3-year average of 100.15% and a median of 2.36% in 2025 define the central range for Return on Sales.
  • Peak YoY movement for Return on Sales: skyrocketed 44448bps in 2024, then grew 7bps in 2025.
  • Iovance Biotherapeutics' Return on Sales stood at 241.41% in 2023, then surged by 100bps to 1.07% in 2024, then rose by 22bps to 0.83% in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Return on Sales are 0.83% (Q4 2025), 1.35% (Q3 2025), and 1.86% (Q2 2025).